About this trial
This is a single-arm, open-label clinical trial involving 100 participants who will undergo a total participation period of 12 weeks.
Eligibility criteria
Qualifiers
Providing written informed consent
Males and females of at least 18 years old
Minimum 4 weeks on GLP-1 (f.e Ozempic®, Wegovy®, Mounjaro®, etc.) and maximum 1 year on GLP-1
Body Mass Index (BMI) ≥ 25 AND ≤ 30
Disqualifiers
Having had any type of bariatric surgery, or planned bariatric surgery during the period of trial participation.
Suffering from a severe chronic disease (e.g., cancer, HIV, hepatic or renal impairment, diabetes type I), inflammatory bowel disease (IBD), Coeliac Disease, and/or being immunocompromised.
Suffering from any uncontrolled endocrine disorder
Having used any antibiotic treatment in the 2 months prior to enrollment.
Trial design
Treatments tested in this trial
- Multivitamin and a Probiotic